Since validating the beneficial effect of BTK inhibition in repressing B-cell activity, we asked whether BTK inhibition with zanubrutinib alleviates disease severity in NMO mice, since up-regulated expression of BTK can be seen in NMO mouse model (Fig. 3B). This evidence concerns the gene BTK and neuromyelitis optica.